Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


53P - Expression of sodium-dependent phosphate transporter NaPi2b is downregulated in malignant ovarian tumors after neoadjuvant chemotherapy


06 Oct 2021




Alsina Nurgalieva


Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740


A.K. Nurgalieva1, S. Safina2, E. Shakirova2, V. Filonenko3, V. Skripova4, L. Bulatova4, D. Savenkova4, M. Bogdanov5, R. Kiyamova4

Author affiliations

  • 1 Kazan Federal University, Kazan/RU
  • 2 Republican Clinical Oncological Dispensary, 420029 - Kazan/RU
  • 3 Institute of Molecular Biology and Genetics, NAS of Ukraine, 3680 - Kyiv/UA
  • 4 Kazan Federal University, 420008 - Kazan/RU
  • 5 University of Texas Health Science Center, 77030 - Houston/US

Abstract 53P


The membrane protein NaPi2b (SLC34A2 gene) is overexpressed in ovarian cancer and other malignancies including thyroid, lung, breast, and others. Currently, NaPi2b-specific therapeutic monoclonal antibodies XMT1536 and XMT-1592 are successfully undergoing clinical trials for the treatment of ovarian and non-small cell lung cancers, demonstrating safety and clinical efficacy. These humanized auristatin F (AF-HPA) conjugated antibodies are created on the dolaflexin and dolasynthen technology platforms respectively. We aimed to evaluate NaPi2b as a target for antibody therapy and molecular marker for diagnostics and predicting the course and outcome of ovarian cancer disease.


The analysis of SLC34A2 gene expression in 48 ovarian tumors was performed using real-time PCR, droplet digital PCR, and western blot analysis. Statistical analysis was performed taking into account various clinicopathological characteristics of the ovarian cancer patients, including the stage of the disease, the tumor grade, the presence of ascites and the applying of neoadjuvant chemotherapy which was predominantly carried out according to the TCb regimen (carboplatin and paclitaxel).


It was shown that expression of the NaPi2b transporter is downregulated in tumors of patients who received neoadjuvant chemotherapy. This fact allowed us to suggest that ovarian cancer patients after neoadjuvant therapy may be not sensitive to targeted drugs directed against the NaPi2b transporter due to the loss of its expression. We found no relationships in the expression level of the NaPi2b transporter with the survival rate of ovarian cancer patients, as well as with tumor grade, and presence of ascites. The NaPi2b showed also a tendency to be downregulated at late stage of disease most likely due to low degree of differentiation of tumor cells.


Thus, the NaPi2b protein abundance is lower in tumor ovarian cells of patients who had received neoadjuvant therapy. This study suggests that the level of expression of the sodium-dependent phosphate NaPi2b transporter gene can serve as a potential marker for the monitoring and predicting responses to neoadjuvant and targeted therapy in patients with ovarian cancer.

Legal entity responsible for the study

Kazan Federal University.


Kazan Federal University, state assignment in the sphere of scientific activities; the Russian Science Foundation (project no. 20-14-00166); part of Kazan Federal University Strategic Academic Leadership Program.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.